A REVIEW OF ABBV-744 IN COMBINATION WITH IMMUNOTHERAPY

In Phase C, participants will get ABBV-744 and oral navitoclax. In Phase D, individuals will get ABBV-744 and ruxolitinib. Participants will acquire treatment right up until condition progression or the members are unable to tolerate the study drugs.There might be increased treatment stress for members Within this trial compared to their typical of